Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Hair systems require frequent maintenance and can be costly, but a DIY approach with bi-weekly changes can help manage these issues. Minoxidil and finasteride were tried but not consistently used due to side effects and personal preferences.

A 34-year-old male is experiencing hair loss on the sides of his head, with inflammation and itchiness, while the top remains thick. He is using topical dutasteride and keto shampoo to address the issue.

Anxious_Bee_67's 4 month progress with a hair loss treatment regimen of 1 mg oral finasteride once a day and topical minoxidil twice a day, which has brought "hope" to others who are fighting the Norwood Reaper. Replies include encouragement for further progress and advice on other treatments that can be used in conjunction with the current ones.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A 19-year-old reports positive hair regrowth using oral minoxidil and finasteride, with no side effects. The conversation includes advice on consulting a dermatologist and exploring alternative treatments.

19-year-old with Lichen Planopilaris tried various treatments unsuccessfully. Now considering hair systems, seeking experiences and opinions.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A user's 4-month hair loss progress, which included treatments such as topical finasteride/minoxidil, microneedling, and Nizoral; with others commenting on the great results achieved so far.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A user shared their 4-month progress pictures after using Minoxidil, finasteride, micro-needling, Nizoral, and scalp massage for hair loss. They're now switching from topical to oral finasteride to maintain the results.

The user shared their 4-month hair loss progress, noting initial hair loss followed by improvement. They used a dermaroller twice a week with varying needle sizes.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

A user named "bmbshell" who was dealing with hair loss and initially tried to fix it with a hair system before deciding to try finasteride, dutasteride, minoxidil, microneedling, and biotin supplements. They documented their progress over the past 1 year and 3 months, showing how effective these treatments were in regrowing their hair.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The user is using oral minoxidil and finasteride for hair loss and plans to add topical minoxidil and a dermaroller. They also use ketoconazole shampoo to support hair regrowth.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

A user shared their 4-month hair regrowth progress using oral finasteride and topical minoxidil, reporting no side effects and positive feedback on their appearance. The post sparked debate, with many users doubting the authenticity of the photos, while others congratulated the user on their impressive results.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.